TABUTEAU HERRIOT
SEC CIK 1219927 · EDGAR
BoughtSold
Companies
| Ticker | Company | Title | Holding | Bought | Sold | Trades | First | Last |
|---|---|---|---|---|---|---|---|---|
| AXSM | Axsome Therapeutics, Inc. | CEO, Dir, 10% | 11.9K | — | $110.58M | 18 | 2025-09-12 | 2026-08-05 |
Most active insiders at AXSM, 12 months
| # | Insider | Title | Bought | Sold |
|---|---|---|---|---|
| 1 | TABUTEAU HERRIOT | CEO, Dir, 10% | — | $103.22M |
| 2 | Pizzie Nick | CFO | — | $10.18M |
| 3 | Jacobson Mark L. | COO | — | $8.90M |
| 4 | Coleman Mark | Dir | — | $8.21M |
| 5 | Saad Mark E | Dir | — | $6.21M |
| 6 | Maizel Ari | Chief Commercial Off | — | $2.75M |
| 7 | Mahony Susan | Dir | — | $145.0K |
| 8 | JEFFS ROGER | Dir | — | $141.7K |
Transactions 18
| X | Filed | Traded | Ticker | Company | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| DMT | 2026-08-07 19:00 | 2026-08-05+ | AXSM | Axsome Therapeutics, Inc. | TABUTEAU HERRIOT | CEO, Dir, 10% | M - OptEx | $4.95 | +49.7K | 11.9K | New | +$245.8K |
| DMT | 2026-08-07 19:00 | 2026-08-05+ | AXSM | Axsome Therapeutics, Inc. | TABUTEAU HERRIOT | CEO, Dir, 10% | S - Sale+OE | $212.19 | -49.7K | 7,229 | -87% | -$10.54M |
| DT | 2026-07-01 19:30 | 2026-07-01 | AXSM | Axsome Therapeutics, Inc. | TABUTEAU HERRIOT | CEO, Dir, 10% | M - OptEx | $4.95 | +49.7K | 56.9K | +687% | +$245.8K |
| DT | 2026-07-01 19:30 | 2026-07-01 | AXSM | Axsome Therapeutics, Inc. | TABUTEAU HERRIOT | CEO, Dir, 10% | S - Sale+OE | $240.25 | -49.7K | 7,229 | -87% | -$11.93M |
| DT | 2026-06-09 17:17 | 2026-06-09 | AXSM | Axsome Therapeutics, Inc. | TABUTEAU HERRIOT | CEO, Dir, 10% | M - OptEx | $4.95 | +49.7K | 56.9K | +687% | +$245.9K |
| DT | 2026-06-09 17:17 | 2026-06-09 | AXSM | Axsome Therapeutics, Inc. | TABUTEAU HERRIOT | CEO, Dir, 10% | S - Sale+OE | $241.01 | -49.7K | 7,229 | -87% | -$11.97M |
| DT | 2026-02-02 | 2026-02-02 | AXSM | Axsome Therapeutics, Inc. | TABUTEAU HERRIOT | CEO, Dir, 10% | S - Sale+OE | $185.60 | -32.4K | 7,229 | -82% | -$6.02M |
| DT | 2026-02-02 | 2026-02-02 | AXSM | Axsome Therapeutics, Inc. | TABUTEAU HERRIOT | CEO, Dir, 10% | M - OptEx | $8.02 | +32.4K | 39.6K | +448% | +$259.9K |
| DMT | 2026-01-07 | 2026-01-05+ | AXSM | Axsome Therapeutics, Inc. | TABUTEAU HERRIOT | CEO, Dir, 10% | M - OptEx | $8.02 | +139.4K | 36.7K | New | +$1.12M |
| DMT | 2026-01-07 | 2026-01-05+ | AXSM | Axsome Therapeutics, Inc. | TABUTEAU HERRIOT | CEO, Dir, 10% | S - Sale+OE | $171.30 | -139.4K | 7,229 | -95% | -$23.88M |
| DMT | 2025-12-04 | 2025-12-02+ | AXSM | Axsome Therapeutics, Inc. | TABUTEAU HERRIOT | CEO, Dir, 10% | M - OptEx | $8.02 | +80.0K | 56.5K | New | +$641.4K |
| DMT | 2025-12-04 | 2025-12-02+ | AXSM | Axsome Therapeutics, Inc. | TABUTEAU HERRIOT | CEO, Dir, 10% | S - Sale+OE | $145.66 | -80.0K | 7,229 | -92% | -$11.65M |
| DMT | 2025-11-05 | 2025-11-03+ | AXSM | Axsome Therapeutics, Inc. | TABUTEAU HERRIOT | CEO, Dir, 10% | S - Sale+OE | $133.07 | -163.9K | 7,229 | -96% | -$21.82M |
| DMT | 2025-11-05 | 2025-11-03+ | AXSM | Axsome Therapeutics, Inc. | TABUTEAU HERRIOT | CEO, Dir, 10% | M - OptEx | $8.02 | +163.9K | 98.9K | New | +$1.31M |
| DMT | 2025-10-08 | 2025-10-06+ | AXSM | Axsome Therapeutics, Inc. | TABUTEAU HERRIOT | CEO, Dir, 10% | M - OptEx | $8.02 | +45.4K | 26.4K | New | +$364.0K |
| DMT | 2025-10-08 | 2025-10-06+ | AXSM | Axsome Therapeutics, Inc. | TABUTEAU HERRIOT | CEO, Dir, 10% | S - Sale+OE | $119.38 | -45.4K | 7,229 | -86% | -$5.42M |
| DMT | 2025-09-16 | 2025-09-12+ | AXSM | Axsome Therapeutics, Inc. | TABUTEAU HERRIOT | CEO, Dir, 10% | S - Sale+OE | $117.08 | -62.9K | 7,229 | -90% | -$7.36M |
| DMT | 2025-09-16 | 2025-09-12+ | AXSM | Axsome Therapeutics, Inc. | TABUTEAU HERRIOT | CEO, Dir, 10% | M - OptEx | $8.02 | +62.9K | 26.9K | New | +$504.3K |
Purchase Sale Sale after option exercise All abbreviations